治疗乙肝药物阿德福韦酯的专利分析  

Analysis of Patents in Adefovir Related to HBV

作　　者：李瑶[1] 童瑶[1] 

机构地区：[1]国家知识产权局专利局专利审查协作天津中心化学发明审查部,天津300000

出　　处：《广东化工》2017年第7期182-183,167,共3页Guangdong Chemical Industry

摘　　要：阿德福韦酯是美国Gilead Science Inc.研发的新一代核苷酸类抗乙型肝炎病毒药物,能够用于治疗对拉米夫定耐药的患者。本文对阿德福韦酯全球专利进行分析,主要涉及专利申请量趋势和技术分支等方面。通过梳理其技术发展过程,为中国企业和研究结构提供抗乙肝药物科研决策提供数据支持,使其在药物研发、专利保护方面更加有针对性,从而赢得市场。Adefovir dipivoxil is a novol acyclic nucleoside analogue developed by Gilead Science Inc., tbr the treatment of patients with lamivudine resistance. By searching adefovir dipivoxil patents related to HBV, we review and analyze the global patents about adefovir dipivoxil, especially involving patent applications and technical branchs. Through carding technology development process, we provide data support for domestic companies and research institutions in order to protect patent and research drug more effectively and win the market.

关 键 词：吉利德公司 乙型肝炎病毒 阿德福韦酯 专利 

分 类 号：R914[医药卫生—药物化学]